Scorr-Insert
X

Find Novel Oncology Drugs in Clinical Development in CHINA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sintilimab

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: MD Anderson

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 18, 2020

            Details:

            The collaboration aims at providing opportunities for Innovent to pursue approval of sintilimab by the U.S. FDA for multiple rare cancer indications in addition to larger cancer indications for sintilimab that Innovent is independently pursuing for approval as well.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GC027

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2020

            Details:

            GC027 is the first product candidate developed using TruUCAR™ to treat relapsed or refractory (R/R) T-cell malignancies.